Fumihiko Urabe, MD, presented “Novel Combination of Circulating miRNAs for Specific Detection in Prostate Cancer” for the Grand Rounds in Urology audience in November 2019.
How to cite: Urabe, Fumihiko. “Novel Combination of Circulating miRNAs for Specific Detection in Prostate Cancer” November, 2019. Accessed Nov 2024. https://dev.grandroundsinurology.com/novel-combination-of-circulating-mirnas-for-specific-detection-in-prostate-cancer/
Novel Combination of Circulating miRNAs for Specific Detection in Prostate Cancer -Summary:
Fumihiko Urabe, MD, discusses a study for which he was the lead author, entitled “Large-scale Circulating microRNA Profiling for the Liquid Biopsy of Prostate Cancer.” This study investigated the potential use of micro-RNA (miRNA) as an improved biomarker for detecting prostate cancer. He details how his team found 16 miRNAs related to prostate cancer which displayed high specificity and sensitivity in detection, and how extracting miRNA is preferable to the risks and invasiveness of prostate biopsy.
ABOUT THE AUTHOR
Fumihiko Urabe, MD, is a Clinical Associate in the Department of Urology at the Jikei University School of Medicine in Tokyo, Japan. He graduated from the Jikei University School of Medicine in 2012 and completed his residency at the same institution. He was a research fellow in Professor Takahiro Ochiya’s Lab at the National Cancer Center, also in Tokyo, from 2016 to 2018. His research focuses on cancer biology, microRNAs (miRNAs), liquid biopsy, exosomes, and extracellular vesicles in urological cancers. Recently, his research group focused on serum miRNA and launched a national project in Japan, entitled “Development and Diagnostic Technology for Detection of miRNA in Body Fluids.” The aims of this project are to standardize platforms for evaluation of serum miRNA profiles of 13 types of human cancers, including prostate cancer and bladder cancer, using large sample sets (N>40,000). As the lead author, he published the results of this project in 2019. Now his group has started collecting fresh samples prospectively and is planning to validate his retrospective results within three years.
